Zaza Mezvrishvili

Learn More
The aim of our study was to assess the feasibility of bleomycin omission from two cycles of adjuvant bleomycin, etoposide and cysplatin (BEP) chemotherapy in patients with clinical stage I non-seminomatous germ cell tumors (NSGCT). A total of 41 patients with high risk clinical stage I NSGCT of the testis were treated with adjuvant chemotherapy at our(More)
OBJECTIVE To assess the feasibility of bleomycin omission from second and third cycles of bleomycin, etoposide and cisplatin (BEP) chemotherapy in low-volume stage II nonseminomatous germ cell tumor patients who achieve a normal tumor marker level after the first cycle of treatment. MATERIALS AND METHODS Out of 59 nonseminomatous testicular cancer(More)
OBJECTIVE In nonseminomatous testicular cancer patients with normal serum tumor markers and no distant metastasis, postorchiectomy surgery is a valid treatment option if the disease extension into the retroperitoneum is not advanced. We assessed the ability of ultrasound (US) to exclude the presence of bulky retroperitoneal disease. MATERIALS AND METHODS(More)
To assess the efficacy of three cycles of etoposide and cisplatin (EP) chemotherapy in the patients with serological disease only after orchiectomy. Fifteen patients with nonseminomatous germ cell tumors of the testis and elevated serum tumor markers as the only evidence of persistent disease following radical orchiectomy (clinical stage IS cancer), were(More)
Nerve sparing retroperitoneal lymph node dissection is standard treatment method for early stage non-seminomatous germ cell tumor. However, an alternative approaches (surveillance policy, adjuvant and primary chemotherapy) have approximately the same capability for cure. Therefore, the current debate is to decide which is less morbid for the patient at(More)
The clinical results of radiotherapy in low-stage seminoma are excellent with negligible early morbidity. However, in a long-term follow-up various complications may occur. On the other hand, experience in nonseminomas shows that surgical morbidity has decreased markedly after invention of a nerve-sparing technique. These issues served as a rationale for us(More)
The goal of our study was to assess the feasibility of usage of chemotherapy regimens with reduced intensity in subgroups of selected patients with good-prognosis metastatic nonseminomatous germ cell tumor (NSGCT) of the testis. 18 patients with low-volume stage II NSGCT who achieved normal tumor marker level after the first cycle of cisplatin, etoposide(More)
  • 1